BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38740899)

  • 1. Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC.
    Hayhow TG; Williamson B; Lawson M; Cureton N; Braybrooke EL; Campbell A; Carbajo RJ; Cheraghchi-Bashi A; Chiarparin E; Diène CR; Fallan C; Fisher DI; Goldberg FW; Hopcroft L; Hopcroft P; Jackson A; Kettle JG; Klinowska T; Künzel U; Lamont G; Lewis HJ; Maglennon G; Martin S; Gutierrez PM; Morrow CJ; Nikolaou M; Nissink JWM; O'Shea P; Polanski R; Schade M; Scott JS; Smith A; Weber J; Wilson J; Yang B; Crafter C
    Commun Biol; 2024 May; 7(1):563. PubMed ID: 38740899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
    Rodriguez-Gonzalez A; Cyrus K; Salcius M; Kim K; Crews CM; Deshaies RJ; Sakamoto KM
    Oncogene; 2008 Dec; 27(57):7201-11. PubMed ID: 18794799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α.
    Dai Y; Yue N; Gong J; Liu C; Li Q; Zhou J; Huang W; Qian H
    Eur J Med Chem; 2020 Feb; 187():111967. PubMed ID: 31865016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutathione-responsive PROTAC for targeted degradation of ERα in breast cancer cells.
    Zhou Z; Fan H; Yu D; Shi F; Li Q; Zhang Z; Wang X; Zhang X; Dong C; Sun H; Mi W
    Bioorg Med Chem; 2023 Dec; 96():117526. PubMed ID: 38008041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells.
    Hu B; Hu J
    Breast Cancer Res Treat; 2024 Jan; 203(2):383-396. PubMed ID: 37847455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Stabilized Peptide-Based PROTACs against Estrogen Receptor α.
    Jiang Y; Deng Q; Zhao H; Xie M; Chen L; Yin F; Qin X; Zheng W; Zhao Y; Li Z
    ACS Chem Biol; 2018 Mar; 13(3):628-635. PubMed ID: 29271628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer
    Xie B; Yin Z; Hu Z; Lv J; Du C; Deng X; Huang Y; Li Q; Huang J; Liang K; Zhou HB; Dong C
    J Med Chem; 2023 May; 66(10):6631-6651. PubMed ID: 37161783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway.
    Zhou J; Shen R; Liu J; Deng X; Xin L; Zhou HB; Huang J
    Bioorg Med Chem; 2023 Mar; 82():117235. PubMed ID: 36905762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    Setia N; Almuqdadi HTA; Abid M
    Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen.
    Loren G; Espuny I; Llorente A; Donoghue C; Verdaguer X; Gomis RR; Riera A
    Eur J Med Chem; 2022 Dec; 243():114770. PubMed ID: 36148710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs.
    Cyrus K; Wehenkel M; Choi EY; Lee H; Swanson H; Kim KB
    ChemMedChem; 2010 Jul; 5(7):979-85. PubMed ID: 20512796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel 11β-substituted estradiol conjugates: Transition from ERα agonizts to effective PROTAC degraders.
    Luo G; Li X; Lin X; Lu X; Li Z; Xiang H
    J Steroid Biochem Mol Biol; 2022 Oct; 223():106154. PubMed ID: 35870675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment.
    Xie B; Xu B; Xin L; Wei Y; Guo X; Dong C
    Bioorg Chem; 2023 Aug; 137():106590. PubMed ID: 37163809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
    Kang CH; Lee DH; Lee CO; Du Ha J; Park CH; Hwang JY
    Biochem Biophys Res Commun; 2018 Oct; 505(2):542-547. PubMed ID: 30274779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance.
    Lin X; Xiang H; Luo G
    Eur J Med Chem; 2020 Nov; 206():112689. PubMed ID: 32829249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROTAC Degrader of Estrogen Receptor α Targeting DNA-Binding Domain in Breast Cancer.
    Zhang X; Zhang Z; Xue X; Fan T; Tan C; Liu F; Tan Y; Jiang Y
    ACS Pharmacol Transl Sci; 2022 Nov; 5(11):1109-1118. PubMed ID: 36407946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of
    Chen Z; Hu B; Rej RK; Wu D; Acharyya RK; Wang M; Xu T; Lu J; Metwally H; Wang Y; McEachern D; Bai L; Gersch CL; Wang M; Zhang W; Li Q; Wen B; Sun D; Rae JM; Wang S
    J Med Chem; 2023 Sep; 66(17):12559-12585. PubMed ID: 37647546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pVHL-mediated degradation of HIF-2α regulates estrogen receptor α expression in normoxic breast cancer cells.
    Higashimura Y; Kitakaze T; Harada N; Inui H; Nakano Y; Yamaji R
    FEBS Lett; 2016 Aug; 590(16):2690-9. PubMed ID: 27323688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
    Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
    Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
    Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
    J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.